EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitVergleichsstudieOpen Access · CC BY 4.0

Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries

Rasha A Alshaikh, Diarmuid J Cronin, Dyfrig A Hughes, Caitriona M O'Driscoll

European Journal of Pharmaceutical Sciences · 2026-12 · 227 · 107652

DOI: 10.1016/j.ejps.2026.107652 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Pharmaceutical Sciences, 2026-12. Verfasst von Rasha A Alshaikh und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland. Elec…. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Reimbursement Mechanisms, RNA, Health Services Accessibility. Die Arbeit nennt 177 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Staatssekretariat für Bildung, Forschung und Innovation, European Commission, UKRI.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapies are transforming the treatment landscape for several rare, severe, and previously untreatable diseases. Regulatory approval only permits the medicine to be marketed; it does not determine whether a public health system will fund it. In Europe, this typically relies on national reimbursement bodies, following a Health Technology Assessment (HTA) or comparable processes. Despite the clinical promise of RNA therapeutics, they pose a significant challenge for funding decision makers due to their high costs, limited evidence on long-term effectiveness, and often narrow indications. Therefore, this targeted comparative review was conducted to analyse national HTA decisions and reimbursement policies for selected non-viral RNA therapeutics across six countries: Ireland, England, France, Germany, Canada, and the United States. HTA agencies across the reviewed countries generally issued favourable recommendations for RNA therapeutics reimbursement despite different assessment criteria, citing clinical effectiveness, unmet need, and budget impact as central factors. However, HTA agencies also expressed concerns about long-term benefit, meeting cost-effectiveness thresholds, and limited real-world evidence of these therapeutics. RNA therapeutics were often reimbursed under conditional reimbursement schemes or managed entry pathways. Countries with formal orphan drug pathways or flexible reimbursement mechanisms (e.g. Germany, England) were more likely to facilitate earlier access. With the accelerating growth in new RNA therapeutics, there needs to be consideration of the capacity for, and appropriateness of, current approaches of assessment and reimbursement, as well as the extent to which harmonisation of methods can support equitable and evidence-based patient access across Europe.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Technology Assessment, BiomedicalReimbursement MechanismsRNAHealth Services AccessibilityHumansEuropeCost-Benefit Analysis

Stichwörter der Autor:innen

Antisense oligonucleotidesHealth technology assessment (HTA)Market accessRNA-based therapeuticsReimbursement policymRNA vaccinessiRNA

Substanzen

RNA

Autor:innen und Institutionen

  • School of Pharmacy, University College Cork, Cork, Ireland; Department of Pharmacology and Therapeutics, University College Cork, Cork, Ireland. Electronic address: ralshaikh@ucc.ie.
  • School of Pharmacy, University College Cork, Cork, Ireland.
  • Centre for Health Economics and Medicines Evaluation, Bangor University, Bangor, Wales, UK.

Förderung

  • Staatssekretariat für Bildung, Forschung und Innovation
  • European Commission
  • UKRI

Zitieren

APA

Alshaikh, R. A., Cronin, D. J., Hughes, D. A., & O'Driscoll, C. M. (2026). Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries. European Journal of Pharmaceutical Sciences, 227, 107652. https://doi.org/10.1016/j.ejps.2026.107652

Vancouver

Alshaikh RA, Cronin DJ, Hughes DA, O'Driscoll CM. Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries. European Journal of Pharmaceutical Sciences. 2026;227:107652. doi:10.1016/j.ejps.2026.107652

BibTeX
@article{Alshaikh2026,
  author = {Alshaikh, Rasha A and Cronin, Diarmuid J and Hughes, Dyfrig A and O'Driscoll, Caitriona M},
  title = {Navigating patient access pathways for non-viral RNA-based therapeutics: a comparative review of health technology assessment and reimbursement pathways across six countries},
  journal = {European Journal of Pharmaceutical Sciences},
  year = {2026},
  volume = {227},
  pages = {107652},
  doi = {10.1016/j.ejps.2026.107652}
}
Kostenlos starten →